Sunovion’s Request for Approval of Under-the-Tongue Apomorphine to Treat ‘Off’ Periods Under FDA Review
The U.S. Food and Drug Administration (FDA) has accepted for review its request to approve apomorphine sublingual film (APL-130277)…
Articles by Patricia Inácio, PhD
Psychosis in Parkinson’s Linked to Volume Changes in Specific Area of Brain, Study Says
Psychosis and cognitive impairment in patients with Parkinson’s disease may be linked to structural changes in the brain, namely…
Immunosuppressant Use Linked to Lower Risk of Developing Parkinson’s in Early Study
People who take certain immunosuppressants — medicines that dampen the immune system’s response — appear to have a lower risk…
Dance-movement Therapy May Help Parkinson’s, Other Motor Diseases, Study Finds
New methods to measure brain activity in dancers can be applied to develop new forms of treatment, such as dance-movement therapy, for…
Nerve Cell Signals That Guide Movement Are Complex and Dynamic, Study Finds
Rate hypothesis, a theory that Parkinson’s results from an imbalance in brain signals telling the body to start and stop moving,…
Dopamine Neurons Participate in Forming New Long-term Memories, Study Shows
Dopamine-releasing neurons are important players in the formation of new, long-term memories, research shows. These findings may help develop…
Working Memory Problems Tied to Binge Eating in Patients on Dopamine Replacement Therapy
Deficits in short-term memory, known as working memory, may underlie the compulsive “binge eating” observed in some Parkinson’s patients undergoing…
Most Parkinson’s Patients Show Non-movement Symptoms Like Depression, Sleep Problems, Survey Finds
Nearly all Parkinson’s disease patients experience non-movement symptoms, such as sleep disturbances or depression, which affect their quality of life…
Potential Treatment for Daytime Sleepiness in Parkinson’s Patients Moving to Phase 2 Trial
Theranexus announced it is starting a Phase 2 clinical trial investigating THN102 as a potential therapy for Parkinson’s patients who…
Gocovri Improves Dyskinesia in Parkinson’s Patients Over Long Term, Phase 3 Trial Shows
Gocovri (amantadine) extended release oral capsules provided long-term improvements of motor complications in Parkinson’s disease patients, according to results from…